In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...